Cargando…
Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study
OBJECTIVES: In this large multicentre study, we compared the effectiveness and safety of tocilizumab intravenous versus subcutaneous (SC) in 109 Takayasu arteritis (TAK) patients. METHODS: We conducted a retrospective multicentre study in referral centres from France, Italy, Spain, Armenia, Israel,...
Ejemplares similares
-
Tocilizumab in treatment-naïve patients with Takayasu arteritis: TOCITAKA French prospective multicenter open-labeled trial
por: Mekinian, Arsene, et al.
Publicado: (2020) -
Practical issues encountered while determining Minimal Clinically Important Difference in Patient-Reported Outcomes
por: Woaye-Hune, Pascal, et al.
Publicado: (2020) -
Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia
por: Jachiet, Vincent, et al.
Publicado: (2021) -
Efficacy and safety of anakinra in adults presenting deteriorating respiratory symptoms from COVID-19: A randomized controlled trial
por: Audemard-Verger, Alexandra, et al.
Publicado: (2022) -
Prevalence of cardiovascular risk factors, the use of statins and of aspirin in Takayasu Arteritis
por: Laurent, Charlotte, et al.
Publicado: (2021)